466 related articles for article (PubMed ID: 27431865)
1. Ursolic Acid Loaded PLGA Nanoparticles: in vitro and in vivo Evaluation to Explore Tumor Targeting Ability on B16F10 Melanoma Cell Lines.
Baishya R; Nayak DK; Kumar D; Sinha S; Gupta A; Ganguly S; Debnath MC
Pharm Res; 2016 Nov; 33(11):2691-703. PubMed ID: 27431865
[TBL] [Abstract][Full Text] [Related]
2. Garcinol loaded vitamin E TPGS emulsified PLGA nanoparticles: preparation, physicochemical characterization, in vitro and in vivo studies.
Gaonkar RH; Ganguly S; Dewanjee S; Sinha S; Gupta A; Ganguly S; Chattopadhyay D; Chatterjee Debnath M
Sci Rep; 2017 Apr; 7(1):530. PubMed ID: 28373669
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
4. Formulation and evaluation of tacrolimus-loaded galactosylated Poly(lactic-co-glycolic acid) nanoparticles for liver targeting.
Mistry NP; Desai JL; Thakkar HP
J Pharm Pharmacol; 2015 Oct; 67(10):1337-48. PubMed ID: 25944126
[TBL] [Abstract][Full Text] [Related]
5. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
Şengel-Türk CT; Hasçiçek C; Dogan AL; Esendagli G; Guc D; Gönül N
Drug Dev Ind Pharm; 2012 Sep; 38(9):1107-16. PubMed ID: 22348284
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies.
Jose S; Juna BC; Cinu TA; Jyoti H; Aleykutty NA
Colloids Surf B Biointerfaces; 2016 Jun; 142():307-314. PubMed ID: 26970818
[TBL] [Abstract][Full Text] [Related]
7. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system.
Wang H; Liu J; Tao S; Chai G; Wang J; Hu FQ; Yuan H
Int J Nanomedicine; 2015; 10():5671-85. PubMed ID: 26388691
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin.
Pradhan R; Ramasamy T; Choi JY; Kim JH; Poudel BK; Tak JW; Nukolova N; Choi HG; Yong CS; Kim JO
Carbohydr Polym; 2015 Jun; 123():313-23. PubMed ID: 25843864
[TBL] [Abstract][Full Text] [Related]
9. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
[TBL] [Abstract][Full Text] [Related]
10. Poly((D,L)lactic-glycolic)acid-star glucose nanoparticles for glucose transporter and hypoglycemia-mediated tumor targeting.
Park JH; Cho HJ; Kim DD
Int J Nanomedicine; 2017; 12():7453-7467. PubMed ID: 29066894
[TBL] [Abstract][Full Text] [Related]
11. A Carrier-Free Folate Receptor-Targeted Ursolic Acid/Methotrexate Nanodelivery System for Synergetic Anticancer Therapy.
Lan JS; Qin YH; Liu L; Zeng RF; Yang Y; Wang K; Ding Y; Zhang T; Ho RJY
Int J Nanomedicine; 2021; 16():1775-1787. PubMed ID: 33692622
[TBL] [Abstract][Full Text] [Related]
12. Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles.
Sharma D; Sharma RK; Sharma N; Gabrani R; Sharma SK; Ali J; Dang S
AAPS PharmSciTech; 2015 Oct; 16(5):1108-21. PubMed ID: 25698083
[TBL] [Abstract][Full Text] [Related]
13. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
14. Folate decorated epigallocatechin-3-gallate (EGCG) loaded PLGA nanoparticles; in-vitro and in-vivo targeting efficacy against MDA-MB-231 tumor xenograft.
Kazi J; Sen R; Ganguly S; Jha T; Ganguly S; Chatterjee Debnath M
Int J Pharm; 2020 Jul; 585():119449. PubMed ID: 32464231
[TBL] [Abstract][Full Text] [Related]
15. Poly(lactic acid) nanoparticles loaded with ursolic acid: Characterization and in vitro evaluation of radical scavenging activity and cytotoxicity.
Antônio E; Antunes ODR; de Araújo IS; Khalil NM; Mainardes RM
Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():156-166. PubMed ID: 27987693
[TBL] [Abstract][Full Text] [Related]
16. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
17. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
18. Development of bicalutamide-loaded PLGA nanoparticles: preparation, characterization and in-vitro evaluation for the treatment of prostate cancer.
Ray S; Ghosh Ray S; Mandal S
Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):944-954. PubMed ID: 27327352
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells.
Mo L; Hou L; Guo D; Xiao X; Mao P; Yang X
Int J Pharm; 2012 Oct; 436(1-2):815-24. PubMed ID: 22846410
[TBL] [Abstract][Full Text] [Related]
20. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
